Bolt Biotherapeutics, Inc.

NasdaqCM:BOLT Stock Report

Market Cap: US$18.7m

Bolt Biotherapeutics Valuation

Is BOLT undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of BOLT when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate BOLT's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate BOLT's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for BOLT?

Key metric: As BOLT is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for BOLT. This is calculated by dividing BOLT's market cap by their current revenue.
What is BOLT's PS Ratio?
PS Ratio1.9x
SalesUS$9.78m
Market CapUS$18.68m

Price to Sales Ratio vs Peers

How does BOLT's PS Ratio compare to its peers?

The above table shows the PS ratio for BOLT vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average9.9x
CARM Carisma Therapeutics
0.9x-47.0%US$18.8m
HOOK HOOKIPA Pharma
0.4x-31.3%US$21.5m
GOVX GeoVax Labs
5.1x56.5%US$15.8m
BRTX BioRestorative Therapies
33x68.2%US$12.5m
BOLT Bolt Biotherapeutics
1.9x24.4%US$18.7m

Price-To-Sales vs Peers: BOLT is good value based on its Price-To-Sales Ratio (1.9x) compared to the peer average (9.9x).

Price to Sales Ratio vs Industry

How does BOLT's PS Ratio compare vs other companies in the US Biotechs Industry?

137 CompaniesPrice / SalesEstimated GrowthMarket Cap
Industry Avg.10.9x20.7%
BOLT Bolt Biotherapeutics
 1.9x24.4%US$18.68m
BIIB Biogen
2.1x-0.2%US$20.59b
INCY Incyte
3.3x4.0%US$13.96b
BOLT 1.9xIndustry Avg. 10.9xNo. of Companies137PS01632486480+
137 CompaniesEstimated GrowthMarket Cap
Industry Avg.10.9x28.8%
BOLT Bolt Biotherapeutics
 1.9x3.6%US$18.68m
No more companies

Price-To-Sales vs Industry: BOLT is good value based on its Price-To-Sales Ratio (1.9x) compared to the US Biotechs industry average (10.9x).

Price to Sales Ratio vs Fair Ratio

What is BOLT's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

BOLT PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio1.9x
Fair PS Ratio0.02x

Price-To-Sales vs Fair Ratio: BOLT is expensive based on its Price-To-Sales Ratio (1.9x) compared to the estimated Fair Price-To-Sales Ratio (0x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst BOLT forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$0.49
US$1.75
+258.6%
14.3%US$2.00US$1.50n/a2
Feb ’26US$0.49
US$1.75
+257.1%
14.3%US$2.00US$1.50n/a2
Jan ’26US$0.54
US$1.75
+227.0%
14.3%US$2.00US$1.50n/a2
Dec ’25US$0.64
US$1.75
+173.2%
14.3%US$2.00US$1.50n/a2
Nov ’25US$0.66
US$1.75
+165.8%
14.3%US$2.00US$1.50n/a2
Oct ’25US$0.65
US$1.75
+170.1%
14.3%US$2.00US$1.50n/a2
Sep ’25US$0.68
US$1.58
+133.7%
19.7%US$2.00US$1.25n/a3
Aug ’25US$0.73
US$1.25
+70.1%
16.3%US$1.50US$1.00n/a3
Jul ’25US$0.73
US$1.25
+70.8%
16.3%US$1.50US$1.00n/a3
Jun ’25US$0.76
US$1.94
+156.0%
62.1%US$4.00US$1.00n/a4
May ’25US$1.12
US$4.45
+297.3%
52.7%US$8.00US$1.25n/a5
Apr ’25US$1.50
US$4.45
+196.7%
52.7%US$8.00US$1.25n/a5
Mar ’25US$1.21
US$4.45
+267.8%
52.7%US$8.00US$1.25n/a5
Feb ’25US$1.11
US$4.45
+300.9%
52.7%US$8.00US$1.25US$0.495
Jan ’25US$1.12
US$4.45
+297.3%
52.7%US$8.00US$1.25US$0.545
Dec ’24US$0.89
US$4.80
+439.3%
40.4%US$8.00US$3.00US$0.645
Nov ’24US$1.00
US$4.80
+380.0%
40.4%US$8.00US$3.00US$0.665
Oct ’24US$1.04
US$4.80
+361.5%
40.4%US$8.00US$3.00US$0.655
Sep ’24US$1.08
US$5.25
+386.1%
36.6%US$8.00US$3.00US$0.684
Aug ’24US$1.32
US$5.20
+293.9%
37.3%US$8.00US$3.00US$0.735
Jul ’24US$1.28
US$5.20
+306.3%
37.3%US$8.00US$3.00US$0.735
Jun ’24US$1.70
US$5.20
+205.9%
37.3%US$8.00US$3.00US$0.765
May ’24US$1.56
US$5.20
+233.3%
37.3%US$8.00US$3.00US$1.125
Apr ’24US$1.39
US$5.20
+274.1%
37.3%US$8.00US$3.00US$1.505
Mar ’24US$1.65
US$5.20
+215.2%
37.3%US$8.00US$3.00US$1.215
Feb ’24US$1.47
US$5.20
+253.7%
37.3%US$8.00US$3.00US$1.115
Analyst Price Target
Consensus Narrative from 2 Analysts
US$1.75
Fair Value
72.1% undervalued intrinsic discount
2
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/23 07:06
End of Day Share Price 2025/02/21 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Bolt Biotherapeutics, Inc. is covered by 6 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Michael SchmidtGuggenheim Securities, LLC
Edward WhiteH.C. Wainwright & Co.
Soumit RoyJonesTrading Institutional Services, LLC